Table 4 Treatment-related toxicity graded by the Common Toxicity Criteria (version 3.0): overall assessment of adverse events per cycle (n=238)
Toxicity | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
Hematological | Â | Â | Â | Â |
   Anemia | 48 (20.2) | 42 (17.6) | 4 (1.7) | 0 |
   Neutropenia | 32 (13.4) | 38 (16.0) | 6 (2.5) | 1 (0.4) |
   Thrombocytopenia | 10 (4.2) | 14 (5.9) | 4 (1.7) | 0 |
Gastrointestinal | Â | Â | Â | Â |
   Nausea | 26 (10.9) | 10 (4.2) | 0 | 0 |
   Vomiting | 18 (7.6) | 8 (3.4) | 3 (1.3) | 1 (0.4)* |
   Dyspepsia | 7 (2.9) | 0 | 1 (0.4)° | 0 |
   Constipation | 8 (3.4) | 6 (2.5) | 1 (0.4)* | 0 |
   Diarrhea | 5 (2.1) | 7 (2.9) | 1 (0.4)° | 0 |
   Rectal bleeding | 0 | 1 (0.4)° | 0 | 0 |
   Abdominal pain | 1 (0.4) | 2 (0.8)° | 0 | 0 |
   AST/ALT elevation | 4 (1.7) | 0 | 0 | 0 |
Neurological | Â | Â | Â | Â |
   Hypoacusia | 1 (0.4) | 1 (0.4) | 0 | 0 |
   Sensitive Neurotoxicity | 2 (0.8) | 0 | 0 | 0 |
   Motor Neurotoxicity | 2 (0.8) ° | 0 | 0 | 0 |
Vertigo | 1 (0.4)° | 0 | 0 | 0 |
Fatigue | 13 (5.5) | 6 (2.5) | 2 (0.8) | 0 |
Venous thrombosis | 1 (0.4) | 0 | 0 | 0 |
Skin (erythema/desquamation) | 5 (2.1) | 1 (0.4)° | 0 | 0 |
Hypertension | 0 | 1 (0.4) | 1 (0.4) ° | 0 |
Renal failure | 0 | 1 (0.4) | 0 | 0 |
Carboplatin HSR | 1 (0.4) | 2 (0.8) | 4 (1.7)° | 0 |